KLRS Q2 2023 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$47M

Net Income

-$45M

EPS (Diluted)

$-11.00

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$283M

Total Liabilities

$54M

Stockholders' Equity

$229M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$426,000	+100.0%
Operating Income	-$47M	-$45M	-6.0%
Net Income	-$45M	-$45M	-1.4%